Media coverage about Cynosure (NASDAQ:CYNO) has trended somewhat positive recently, Alpha One reports. Alpha One, a unit of Accern, identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cynosure earned a coverage optimism score of 0.05 on Alpha One’s scale. Alpha One also gave news stories about the medical equipment provider an impact score of 50 out of 100, indicating that recent news coverage is somewhat likely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have effected AlphaOne’s analysis:

CYNO has been the subject of a number of recent analyst reports. Northcoast Research downgraded shares of Cynosure from a “buy” rating to a “sell” rating and set a $40.00 price objective for the company. in a research report on Friday, January 6th. TheStreet raised shares of Cynosure from a “hold” rating to a “buy” rating in a research report on Wednesday, January 4th. Zacks Investment Research downgraded shares of Cynosure from a “hold” rating to a “sell” rating in a research report on Monday, January 9th. Northland Securities reaffirmed an “outperform” rating and issued a $60.00 price objective on shares of Cynosure in a research report on Tuesday, January 10th. Finally, Aegis reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Cynosure in a research report on Tuesday, January 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. Cynosure presently has a consensus rating of “Hold” and a consensus target price of $58.63.

Shares of Cynosure (NASDAQ:CYNO) remained flat at $66.00 during midday trading on Wednesday. The stock has a 50-day moving average price of $62.47 and a 200-day moving average price of $50.89. Cynosure has a 52-week low of $39.90 and a 52-week high of $66.65.

Cynosure (NASDAQ:CYNO) last released its quarterly earnings data on Tuesday, February 7th. The medical equipment provider reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. Cynosure had a net margin of 3.56% and a return on equity of 6.86%. The firm earned $122.10 million during the quarter, compared to analysts’ expectations of $119.97 million. During the same period in the previous year, the company earned $0.42 earnings per share. The firm’s quarterly revenue was up 19.2% on a year-over-year basis. On average, analysts predict that Cynosure will post $1.59 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/05/03/cynosure-cyno-earning-somewhat-favorable-news-coverage-analysis-finds.html.

Cynosure Company Profile

Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.

5 Day Chart for NASDAQ:CYNO

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.